Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Solid Biosciences Inc.SLDB · Entity 4915 | Chief Technology Officer | January 29, 2026 | April 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Solid Biosciences Inc.
Report date January 29, 2026 · Filed April 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 54,925 |
Reported balance
After 2026-01-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-29 · Grant · Acquired 54,925 · Balance 54,925 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). F2: Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").
F2: Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2026 Filed Feb 19, 2026 02:31 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 3,616 | $5.82 | $21,057.05 |
DisclosureSEC source: 0001193125-26-057865 · ownership.xml · nonDerivative · entry 2 Herzich Paul · CIK 0001954991 · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,638 F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Mr. Herzich on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Herzich. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.23 to $6.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form. Read SEC document |
| February 13, 2026 Filed Feb 19, 2026 02:31 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 7,187 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-057865 · ownership.xml · derivative · entry 3 Herzich Paul · CIK 0001954991 · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,376 Underlying: Common Stock · 7,187 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). F4 · derivative.exercise_date: The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. F4 · derivative.expiration_date: The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. Read SEC document |
| February 13, 2026 Filed Feb 19, 2026 02:31 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 7,187 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-057865 · ownership.xml · nonDerivative · entry 1 Herzich Paul · CIK 0001954991 · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,254 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 22:56 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 10,905 | $6.44 | $70,248.92 |
DisclosureSEC source: 0001193125-26-041506 · ownership.xml · nonDerivative · entry 1 Herzich Paul · CIK 0001954991 · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,067 F1 · shares: This sale was made to cover withholding taxes following the vesting of previously granted restricted stock units pursuant to a durable automatic sale instruction letter adopted by Mr. Herzich on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Herzich. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.28 to $6.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 01:09 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 26,250 | $6.44 | $168,968.63 |
DisclosureSEC source: 0001193125-26-034076 · ownership.xml · nonDerivative · entry 3 Herzich Paul · CIK 0001954991 · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,972 F3 · shares: This sale was made to cover withholding taxes following the vesting of previously granted PSUs pursuant to a durable automatic sale instruction letter adopted by Mr. Herzich on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Herzich. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.295 to $6.580, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 01:09 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 24,675 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-034076 · ownership.xml · derivative · entry 7 Herzich Paul · CIK 0001954991 · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,025 Underlying: Common Stock · 24,675 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ("RSUs") converts to common stock on a one-for-one basis. F8 · derivative.exercise_date: On January 31, 2025 (the "2025 Grant Date"), the reporting person was granted 98,700 RSUs, with 25% of the original number of shares vesting on each anniversary of the 2025 Grant Date until the fourth such anniversary. F8 · derivative.expiration_date: On January 31, 2025 (the "2025 Grant Date"), the reporting person was granted 98,700 RSUs, with 25% of the original number of shares vesting on each anniversary of the 2025 Grant Date until the fourth such anniversary. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 01:09 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 24,675 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-034076 · ownership.xml · nonDerivative · entry 2 Herzich Paul · CIK 0001954991 · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,222 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each restricted stock unit ("RSUs") converts to common stock on a one-for-one basis. Read SEC document |
| January 29, 2026 Filed Feb 3, 2026 01:09 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 85,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-034076 · ownership.xml · derivative · entry 6 Herzich Paul · CIK 0001954991 · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSUs") converts to common stock on a one-for-one basis. F7 · derivative.exercise_date: The RSUs were granted on the 2026 Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the 2026 Grant Date until the fourth such anniversary. F7 · derivative.expiration_date: The RSUs were granted on the 2026 Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the 2026 Grant Date until the fourth such anniversary. Read SEC document |
| January 29, 2026 Filed Feb 3, 2026 01:09 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 170,000 | $0.00 Strike: $6.60 | $0.00 |
DisclosureSEC source: 0001193125-26-034076 · ownership.xml · derivative · entry 5 Herzich Paul · CIK 0001954991 · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2036-01-29 F6 · derivative.exercise_date: This option was granted on the 2026 Grant Date and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the 2026 Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary. Read SEC document |
| January 29, 2026 Filed Feb 3, 2026 01:09 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionPerformance Stock Units · Derivative | 54,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-034076 · ownership.xml · derivative · entry 4 Herzich Paul · CIK 0001954991 · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 54,925 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance stock unit ("PSUs") converts to common stock on a one-for-one basis. F5 · derivative.exercise_date: The PSUs were granted on June 11, 2024 and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"), subject to the grantee's continued service with the Company (the "Approval Conditions"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the first Performance Milestone was determined to be met on January 29, 2026 (the "2026 Grant Date") resulting in the vesting of the PSUs as to 25% of the underlying shares. F5 · derivative.expiration_date: The PSUs were granted on June 11, 2024 and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"), subject to the grantee's continued service with the Company (the "Approval Conditions"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the first Performance Milestone was determined to be met on January 29, 2026 (the "2026 Grant Date") resulting in the vesting of the PSUs as to 25% of the underlying shares. Read SEC document |
| January 29, 2026 Filed Feb 3, 2026 01:09 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 54,925 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-034076 · ownership.xml · nonDerivative · entry 1 Herzich Paul · CIK 0001954991 · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance stock unit ("PSUs") converts to common stock on a one-for-one basis. Read SEC document |
| January 29, 2026 Filed Apr 21, 2026 20:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 54,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-166733 · ownership.xml · derivative · entry 1 Herzich Paul · CIK 0001954991 · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,925 Underlying: Common Stock · 54,925 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). F2 · derivative.exercise_date: Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027. F2 · derivative.expiration_date: Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027. Read SEC document |
| December 03, 2025 Filed Dec 4, 2025 21:17 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 2,701 | $5.11 | $13,802.11 |
DisclosureSEC source: 0001193125-25-308103 · ownership.xml · nonDerivative · entry 2 Herzich Paul · CIK 0001954991 · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,622 F3 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Mr. Herzich on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Herzich Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 21:17 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 7,239 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-308103 · ownership.xml · derivative · entry 3 Herzich Paul · CIK 0001954991 · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,239 Underlying: Common Stock · 7,239 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). F4 · derivative.exercise_date: The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. F4 · derivative.expiration_date: The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 21:17 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 7,239 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-308103 · ownership.xml · nonDerivative · entry 1 Herzich Paul · CIK 0001954991 · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,323 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). F2 · balance_after: Includes 1,835 and 1,861 shares of the issuer's common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 30, 2025 and November 28, 2025, respectively. Read SEC document |
| August 14, 2025 Filed Aug 18, 2025 20:15 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-109734 · ownership.xml · derivative · entry 2 Herzich Paul · CIK 0001954991 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs"). F1 · derivative.exercise_date: The RSUs (as defined in footnote 2) together with this option were granted on August 14, 2025 (the "Grant Date") and vest over four years, with 50% of the original number of shares vesting on the second anniversary of the Grant Date and 25% of the original number of shares annually thereafter until the fourth such anniversary. F1 · derivative.expiration_date: The RSUs (as defined in footnote 2) together with this option were granted on August 14, 2025 (the "Grant Date") and vest over four years, with 50% of the original number of shares vesting on the second anniversary of the Grant Date and 25% of the original number of shares annually thereafter until the fourth such anniversary. Read SEC document |
| August 14, 2025 Filed Aug 18, 2025 20:15 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $6.17 | $0.00 |
DisclosureSEC source: 0000950170-25-109734 · ownership.xml · derivative · entry 1 Herzich Paul · CIK 0001954991 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2035-08-14 F1 · derivative.exercise_date: The RSUs (as defined in footnote 2) together with this option were granted on August 14, 2025 (the "Grant Date") and vest over four years, with 50% of the original number of shares vesting on the second anniversary of the Grant Date and 25% of the original number of shares annually thereafter until the fourth such anniversary. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 2,688 | $3.96 | $10,644.48 |
DisclosureSEC source: 0000950170-25-022201 · ownership.xml · nonDerivative · entry 2 Herzich Paul · CIK 0001954991 · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,388 F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Mr. Herzich on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Herzich. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 7,187 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-022201 · ownership.xml · derivative · entry 3 Herzich Paul · CIK 0001954991 · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,563 Underlying: Common Stock · 7,187 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). F3 · derivative.exercise_date: The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. F3 · derivative.expiration_date: The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 7,187 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-022201 · ownership.xml · nonDerivative · entry 1 Herzich Paul · CIK 0001954991 · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,076 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). Read SEC document |
| January 31, 2025 Filed Feb 11, 2025 21:42 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 98,700 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-017978 · ownership.xml · derivative · entry 2 Herzich Paul · CIK 0001954991 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,700 Underlying: Common Stock · 98,700 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs"). F3 · derivative.exercise_date: The RSUs were granted on the January 31, 2025 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. F3 · derivative.expiration_date: The RSUs were granted on the January 31, 2025 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 21:42 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 2,777 | $5.60 | $15,550.64 |
DisclosureSEC source: 0000950170-24-133317 · ownership.xml · nonDerivative · entry 2 Herzich Paul · CIK 0001954991 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,182 F3 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted RSUs. The sale does not represent a discretionary trade made by Dr. Herzich. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 21:42 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 7,239 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-133317 · ownership.xml · derivative · entry 3 Herzich Paul · CIK 0001954991 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,478 Underlying: Common Stock · 7,239 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). F4 · derivative.exercise_date: The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. F4 · derivative.expiration_date: The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 21:42 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 7,239 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-133317 · ownership.xml · nonDerivative · entry 1 Herzich Paul · CIK 0001954991 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,959 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). F2 · balance_after: Includes 1,698 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 31, 2024. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 16:02 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 28,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-016185 · ownership.xml · derivative · entry 3 Herzich Paul · CIK 0001954991 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,750 Underlying: Common Stock · 28,750 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs"). F4 · derivative.exercise_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. F4 · derivative.expiration_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 16:02 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 57,500 | $0.00 Strike: $7.85 | $0.00 |
DisclosureSEC source: 0000950170-24-016185 · ownership.xml · derivative · entry 2 Herzich Paul · CIK 0001954991 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,500 Underlying: Common Stock · 57,500 shares Expires 2034-02-13 F2 · derivative.exercise_date: This option was granted on February 13, 2024 (the "Grant Date") and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary. Read SEC document |
| December 04, 2023 Filed Dec 5, 2023 19:31 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 2,968 | $2.77 | $8,232.34 |
DisclosureSEC source: 0000950170-23-068065 · ownership.xml · nonDerivative · entry 2 Herzich Paul · CIK 0001954991 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,270 F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted RSUs. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1). Read SEC document |
| December 02, 2023 Filed Dec 5, 2023 19:31 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 7,238 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-068065 · ownership.xml · derivative · entry 3 Herzich Paul · CIK 0001954991 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,717 Underlying: Common Stock · 7,238 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). F3 · derivative.exercise_date: The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. F3 · derivative.expiration_date: The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. Read SEC document |
| December 02, 2023 Filed Dec 5, 2023 19:31 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 7,238 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-23-068065 · ownership.xml · nonDerivative · entry 1 Herzich Paul · CIK 0001954991 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,238 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). Read SEC document |
| December 02, 2022 Filed Dec 5, 2022 22:48 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 28,955 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-037684 · doc4.xml · derivative · entry 2 Herzich Paul · CIK 0001954991 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,955 Underlying: Common Stock · 28,955 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs"). F3 · derivative.exercise_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. F3 · derivative.expiration_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. Read SEC document |
| December 02, 2022 Filed Dec 5, 2022 22:48 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantStock Option (Right to Buy) · Derivative | 57,900 | $0.00 Strike: $6.77 | $0.00 |
DisclosureSEC source: 0000899243-22-037684 · doc4.xml · derivative · entry 1 Herzich Paul · CIK 0001954991 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,900 Underlying: Common Stock · 57,900 shares Expires 2032-12-02 F1 · derivative.exercise_date: This option was granted on December 2, 2022 (the "Grant Date") and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the Grant Date and 2.0833% of the original number of shares on the first day of each calendar month thereafter until the fourth such anniversary. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.